(:AMTI)

Dec 27, 2023 04:15 pm ET
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and
Nov 29, 2023 08:49 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIN, FRLN, AMTI, ORTX
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: P&F Industries, Inc. (NASDAQ: PFIN)’s...
Nov 28, 2023 05:19 pm ET
APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - A
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Applied Molecular Transport Inc. (NasdaqCM: AMTI) to Cyclo Therapeutics, Inc. (NasdaqCM: CYTH). Under the terms of the proposed transaction, shareholders of Applied Molecular will receive 0.174 shares of Cyclo for each share of Applied Molecular that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Nov 22, 2023 10:23 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHS, AMTI, ESMT, CNSL
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chico’s FAS, Inc. (NYSE: CHS)’s sale...
Nov 09, 2023 04:01 pm ET
Applied Molecular Transport Reports Third Quarter 2023 Financial Results
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023. Recent Business Highlights and Anticipated Milestones Entered into a definitive...
Oct 18, 2023 09:50 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMTI, ICPT, FNCB
NEW YORK, Oct. 18, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Oct 18, 2023 05:26 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – SMMF, AMTI, SATS, AMNB
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2023 ISS Securities Class Action Services Report and headquartered...
Oct 10, 2023 12:47 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMTI, CHS, FNCB, ICPT
NEW YORK, Oct. 10, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Oct 09, 2023 07:02 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger - SMMF, AMTI, SPLK, AVTA
NEW YORK, Oct. 9, 2023 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2023 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
Oct 04, 2023 07:48 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHS, AMTI, CPRI
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chico’s FAS, Inc. (NYSE: CHS)’s...
Oct 04, 2023 05:36 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SPLK, ICPT, CHS, AMTI
NEW YORK, Oct. 4, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Oct 04, 2023 01:52 pm ET
Moore Kuehn Encourages AMTI, SPLK, ICPT, and CHS Investors to Contact Law Firm
NEW YORK, Oct. 4, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.
Oct 03, 2023 11:54 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Intercept Pharmaceuticals, Inc. (Nasdaq – ICPT), Splunk, Inc. (Nasdaq – SPLK), Applied Molecular Transport Inc.
BALA CYNWYD, October 3, 2023 /Globe Newswire/ -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman...
Sep 29, 2023 10:17 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHS, AVID, AMTI, NEM
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chico’s FAS, Inc. (NYSE: CHS)’s sale...
Sep 27, 2023 09:48 pm ET
APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - A
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Applied Molecular Transport Inc. (NasdaqCM: AMTI) to Cyclo Therapeutics, Inc. (NasdaqCM: CYTH). Under the terms of the proposed transaction, shareholders of Applied Molecular will receive 0.174 shares of Cyclo for each share of Applied Molecular that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Sep 26, 2023 03:25 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMTI, NEM, AEL, HCCI
NEW YORK, Sept. 26, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Sep 26, 2023 10:54 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Intercept Pharmaceuticals, Inc. (Nasdaq – ICPT), Splunk, Inc. (Nasdaq – SPLK), Applied Molecular Transport Inc.
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Sep 23, 2023 10:29 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SPLK, CYTH, AMTI
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Splunk Inc. (NASDAQ: SPLK)’s sale to...
Sep 23, 2023 07:09 pm ET
Lifshitz Law PLLC Announces Investigations of EBC, AMTI, SPLK
Eastern Bankshares, Inc. (NASDAQ: EBC) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of EBC and Cambridge Bancorp. Under the terms of the proposed transaction, Cambridge...
Sep 22, 2023 09:31 am ET
Thinking about buying stock in MicroAlgo, Oramed Pharmaceuticals, Limbach Holdings, Niu Technologies, or Applied Molecular Transport?
NEW YORK, Sept. 22, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MLGO, ORMP, LMB, NIU, and AMTI.
Sep 21, 2023 07:49 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SPLK, CYTH, AMTI, EBC
NEW YORK, Sept. 21, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Sep 21, 2023 04:57 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Splunk, Inc. (Nasdaq – SPLK), Applied Molecular Transport Inc. (Nasdaq - AMTI), NextGen Healthcare, Inc. (Nasda
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Sep 21, 2023 08:56 am ET
AMTI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Applied Molecular Transport Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Applied Molecular Transport Inc. (NASDAQ: AMTI) to Cyclo Therapeutics, Inc. for 0.174 shares of Cyclo for each share of Applied Molecular is fair to Applied Molecular shareholders.
Sep 21, 2023 08:05 am ET
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and
Aug 14, 2023 04:01 pm ET
Applied Molecular Transport Reports Second Quarter 2023 Financial Results
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2023. Financial Results for the Second Quarter Ended June 30, 2023 Research and development...
May 11, 2023 04:05 pm ET
Applied Molecular Transport Reports First Quarter 2023 Financial Results
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2023. Recent Business Highlights Engaged MTS Health Partners, L.P. as advisors in a process...
Mar 27, 2023 04:01 pm ET
Applied Molecular Transport Announces Corporate Leadership Change and Process to Explore Strategic Alternatives
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company’s board of directors approved a workforce reduction of approximately 57% of its employee base and the engagement of...
Mar 09, 2023 04:05 pm ET
Applied Molecular Transport Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2022. “We were pleased to...
Mar 03, 2023 08:00 am ET
Applied Molecular Transport Presents Additional Data from Oral AMT-101 Phase 2 FILLMORE Trial in Chronic Pouchitis at ECCO ’23 Congress
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced additional Phase 2 data for oral AMT-101 in chronic pouchitis patients. AMT-101 is an investigational, once-daily, GI-selective, oral fusion of IL-10 and AMT’s proprietary...
Dec 22, 2022 05:30 pm ET
Applied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced top-line Phase 2 results from the LOMBARD monotherapy trial for AMT-101 in biologic-naïve and experienced patients with moderate-to-severe ulcerative colitis (UC). AMT-101 is an...
Nov 10, 2022 08:00 am ET
Applied Molecular Transport Announces FDA Orphan Drug Designation Granted to AMT-101 for Treatment of Pouchitis
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for AMT-101 in patients with pouchitis, an indication with significant unmet medical need and no...
Nov 08, 2022 08:00 am ET
Applied Molecular Transport to Present at Upcoming November Investor Conferences
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced its participation at the following investor conferences: Event: Guggenheim 4th Annual Immunology and Neurology DayFormat: Corporate...
Nov 07, 2022 04:01 pm ET
Applied Molecular Transport Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the third quarter ended September 30, 2022. “Our recent end of Phase 2 meeting...
Sep 20, 2022 08:00 am ET
Applied Molecular Transport Completes Enrollment of Phase 2 LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the company has completed enrollment of the Phase 2 LOMBARD trial for AMT-101 in 105 patients with moderate-to-severe ulcerative...
Aug 10, 2022 12:47 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Applied Molecular Transport Inc. - AMTI
Pomerantz LLP is investigating claims on behalf of investors of Applied Molecular Transport Inc. (“Applied Molecular” or the “Company”) (NASDAQ: AMTI).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or...
Aug 04, 2022 04:01 pm ET
Applied Molecular Transport Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the second quarter ended June 30, 2022. “We were pleased to recently announce...
Aug 02, 2022 03:13 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Applied Molecular Transport Inc. - AMTI
Pomerantz LLP is investigating claims on behalf of investors of Applied Molecular Transport Inc. (“Applied Molecular” or the “Company”) (NYSE: AMTI).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or...
Jul 26, 2022 06:48 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Applied Molecular Transport Inc. - AMTI
Pomerantz LLP is investigating claims on behalf of investors of Applied Molecular Transport Inc. (“Applied Molecular” or the “Company”) (NYSE: AMTI). Such investors are advised to contact Robert S. Willoughby at [email protected] or...
Jul 21, 2022 08:28 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Applied Molecular Transport Inc. - AMTI
NEW YORK, July 21, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Applied Molecular Transport Inc. ("Applied Molecular" or the "Company") (NYSE: AMTI). Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Jul 13, 2022 07:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Applied Molecular Transport Inc. - AMTI
NEW YORK, July 13, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Applied Molecular Transport Inc. ("Applied Molecular" or the "Company") (NYSE: AMTI). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 11, 2022 10:38 am ET
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Applied Molecular Transport Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Applied Molecular Transport Inc. (“Applied Molecular” or “the Company”) (NASDAQ:
Jul 10, 2022 12:54 pm ET
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Applied Molecular Transport Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Applied Molecular Transport Inc. (“Applied Molecular” or “the Company”) (NASDAQ:
Jul 10, 2022 12:01 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Applied Molecular Transport Inc. - AMTI
Pomerantz LLP is investigating claims on behalf of investors of Applied Molecular Transport Inc. (“Applied Molecular” or the “Company”) (NASDAQ: AMTI). Such investors are advised to contact Robert S. Willoughby at [email protected] or...
Jul 06, 2022 08:00 am ET
Applied Molecular Transport Announces Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced top-line Phase 2 results from the MARKET combination trial for AMT-101 in biologic-naïve patients with moderate-to-severe UC. AMT-101 is an investigational, once-daily,...
Jul 05, 2022 04:01 pm ET
Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 MARKET combination trial of AMT-101 (GI- selective, oral fusion of IL-10) with anti-TNFα in biologic-naïve...
Jun 02, 2022 08:00 am ET
Applied Molecular Transport to Present at Upcoming June Investor Conferences
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced its participation in fireside chats at the following investor conferences: Event: Jefferies Global Healthcare ConferencePresentation...
May 18, 2022 08:00 am ET
Applied Molecular Transport Provides Strategy Update
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced strategic actions to focus resources on its lead clinical programs. Strategic Actions Summary: Prioritizing the advancement...
May 09, 2022 04:01 pm ET
Applied Molecular Transport Reports First Quarter 2022 Financial Results and Provides Corporate Update
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022. “We were pleased to recently announce...
May 05, 2022 04:01 pm ET
Applied Molecular Transport to Present at BofA Securities 2022 Healthcare Conference
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the BofA Securities...
Apr 25, 2022 08:00 am ET
Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced positive top-line Phase 2 results from the FILLMORE monotherapy trial for AMT-101 in patients with chronic pouchitis, an orphan indication with significant unmet medical need and...
Apr 24, 2022 01:00 pm ET
Applied Molecular Transport to Report Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 FILLMORE monotherapy trial for AMT-101 (GI- selective, oral fusion of IL-10) in patients with chronic...
Apr 13, 2022 08:00 am ET
Applied Molecular Transport Announces Publication in Tissue Barriers Providing Additional Insight into Company’s Proprietary Technology Platform
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that new insights into the unique mechanism of action utilized by its oral biologic product candidates, including lead clinical...
Apr 06, 2022 08:00 am ET
Applied Molecular Transport Appoints Charlene Banard to its Board of Directors
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Charlene Banard to its Board of Directors. Ms. Banard is an accomplished biopharmaceutical executive with over 30...
Mar 14, 2022 08:00 am ET
Applied Molecular Transport Appoints Industry Veteran Carolyn Finkle as Senior Vice President, Head of Regulatory Affairs
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Carolyn Finkle as senior vice president, head of regulatory affairs. She becomes a member of the AMT executive...
Feb 24, 2022 04:01 pm ET
Applied Molecular Transport Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021. “We are looking...
Feb 10, 2022 08:00 am ET
Applied Molecular Transport to Present at SVB Leerink Virtual 11th Annual Global Healthcare Conference
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the SVB Leerink Virtual...
Jan 27, 2022 04:30 pm ET
Applied Molecular Transport Announces Board Appointments
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of John W. Smither to its Board of Directors and Chair of its Audit Committee. AMT also announced that current...
Nov 15, 2021 08:00 am ET
Applied Molecular Transport to Present at Virtual Jefferies London Healthcare Conference
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Bittoo Kanwar, M.D., chief medical officer, and Liz Bhatt, chief business and strategy officer, will participate in a fireside...
Nov 10, 2021 04:01 pm ET
Applied Molecular Transport Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the third quarter ended September 30, 2021. “I recognize the commitment of the...
Oct 11, 2021 04:01 pm ET
Applied Molecular Transport to Host Virtual Research & Development Day on October 15, 2021
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company will host a virtual Research & Development Day on Friday, October 15, 2021, from 11:00 a.m. – 1:00 p.m. ET. The...
Sep 17, 2021 08:00 am ET
Applied Molecular Transport Announces Upcoming Investor Events in September and October
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company will participate in the following investor events in September and October. Details of the events are as follows:...
Aug 24, 2021 04:01 pm ET
Applied Molecular Transport Appoints Holly Schachner, M.D. to its Board of Directors
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Holly Schachner, M.D. a seasoned and accomplished industry veteran to its Board of Directors. “We are very...
Aug 10, 2021 04:01 pm ET
Applied Molecular Transport Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the second quarter ended June 30, 2021. “We have continued to advance our...
Aug 05, 2021 08:00 am ET
Applied Molecular Transport to Present at Canaccord Genuity’s 41st Annual Growth Conference
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during Canaccord Genuity’s...
Jul 09, 2021 08:00 am ET
Applied Molecular Transport Presents Additional Positive Data from Oral AMT-101 Phase 1b in Ulcerative Colitis at ECCO ‘21 Virtual Congress
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced additional Phase 1b data for oral AMT-101 in ulcerative colitis (UC) patients.   AMT-101 is a novel GI-selective, oral fusion of...
Jun 09, 2021 08:00 am ET
Applied Molecular Transport to Present at JMP Securities Life Sciences Conference
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the JMP Securities Life...
May 26, 2021 08:00 am ET
Applied Molecular Transport to Present at Jefferies Virtual Healthcare Conference
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the Jefferies Virtual...
May 13, 2021 04:01 pm ET
Applied Molecular Transport Reports First Quarter 2021 Financial Results and Provides Corporate Update
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the first quarter ended March 31, 2021. “Our proprietary technology platform...
May 06, 2021 08:00 am ET
Applied Molecular Transport to Present at BofA Securities 2021 Health Care Conference
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the BofA Securities...
Apr 06, 2021 04:01 pm ET
Applied Molecular Transport Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 2,875,000 shares of its common stock, which includes the...
Mar 31, 2021 08:45 pm ET
Applied Molecular Transport Announces Pricing of Public Offering of Common Stock
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a public offering price of $42.00 per...
Mar 29, 2021 04:11 pm ET
Applied Molecular Transport Announces Proposed Public Offering of Common Stock
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of 2,500,000 shares of its common stock. All of the shares in the proposed...
Mar 22, 2021 08:00 am ET
Applied Molecular Transport Appoints Earl Douglas as General Counsel
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that it has appointed Earl Douglas as General Counsel. In his new role, Earl will assume leadership responsibilities for all legal...
Mar 19, 2021 04:05 pm ET
Applied Molecular Transport Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2020. “We have...
Mar 09, 2021 08:00 am ET
Applied Molecular Transport to Present at Oppenheimer 31st Annual Healthcare Conference
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the Oppenheimer 31st...
Mar 01, 2021 08:00 am ET
Applied Molecular Transport Expands Clinical Pipeline and Announces First Subject Dosed in Phase 1a Trial of Oral AMT-126
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the first in human dosing in its Phase 1a clinical trial of oral AMT-126. The randomized, placebo controlled, single ascending dose...
Feb 17, 2021 08:00 am ET
Applied Molecular Transport to Present at SVB Leerink 10th Annual Global Healthcare Conference
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the SVB Leerink 10th...
Jan 19, 2021 08:00 am ET
Applied Molecular Transport Appoints Douglas Rich as Chief Technical Officer
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that it has appointed Douglas Rich as Chief Technical Officer. In his new role, Douglas will assume leadership responsibilities for...
Nov 24, 2020 08:00 am ET
Applied Molecular Transport to Present at Evercore ISI 3rd Annual HealthCONx Conference
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the Evercore ISI 3rd...
Nov 12, 2020 04:05 pm ET
Applied Molecular Transport Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2020. “We continue to make important progress in the development of our...
Nov 11, 2020 08:00 am ET
Applied Molecular Transport to Present at Jefferies Virtual London Healthcare Conference
Applied Molecular Transport (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder of AMT, and Bittoo Kanwar, M.D., chief medical officer of AMT, will...
Nov 10, 2020 08:00 am ET
Applied Molecular Transport Announces Publication of Preclinical Data Demonstrating Potential of Novel Oral IL-10 Biologic Therapeutic (AMT-101) for Inflammatory Diseases in The Journal of Immunology
Applied Molecular Transport (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the unique mechanism of action of AMT-101 and preclinical data supporting its potential as a treatment for ulcerative colitis (UC),...
Sep 22, 2020 08:00 am ET
Applied Molecular Transport to Present at Jefferies Next Generation IBD Therapeutics Virtual Summit
Applied Molecular Transport (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder of AMT, and Bittoo Kanwar, M.D., chief medical officer of AMT, will...
Aug 27, 2020 08:00 am ET
Applied Molecular Transport Announces First Patient Dosed in Phase 2 Study of Oral AMT-101 in Ulcerative Colitis
Applied Molecular Transport (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in a randomized, placebo-controlled, double-blind, multicenter Phase 2a study evaluating the...
Aug 11, 2020 04:00 pm ET
Applied Molecular Transport Reports Second Quarter 2020 Financial Results
Applied Molecular Transport (Nasdaq: AMTI), a clinical-stage biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2020. “As we expected, 2020 has been a transformational year with the successful...
Aug 05, 2020 08:00 am ET
Applied Molecular Transport Named as One of Three Finalists for the Fierce Innovations Awards for AMT-101
Applied Molecular Transport (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that AMT-101 has been named as a biotech innovation finalist in the Fierce Innovation Awards – Life Sciences Edition 2020, a peer-reviewed...
Jun 09, 2020 04:05 pm ET
Applied Molecular Transport Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Applied Molecular Transport (Nasdaq: AMTI), a clinical-stage biopharmaceutical company, today announced the closing of its initial public offering of 12,650,000 shares of its common stock, which includes the exercise in full by the underwriters of...
Jun 04, 2020 10:40 pm ET
Applied Molecular Transport Announces Pricing of Initial Public Offering
Applied Molecular Transport (Nasdaq: AMTI), a clinical-stage biopharmaceutical company, today announced the pricing of its initial public offering of 11,000,000 shares of common stock at a public offering price of $14.00 per share. All of the...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.